Cefcapene (INN) is a third-generation cephalosporin antibiotic.
It was patented in 1985[1] and approved for medical use in 1997[1] in Japan, where it is sold under the Tradename Flomox by Shionogi & Co., Ltd.[2] It is also approved and available as a generic in South Korea[3] and China.[4] It is known to cause severe hypocarnitinemia and associated serious hypoglycaemia, seizures, and encephalopathy in children.[5]
References
- 1 2 Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.
- ↑ "Pharmaceuticals and Medical Devices Safety Information No. 233" (PDF). Pharmaceuticals and Medical Devices Agency. March 2007. Retrieved 2026-08-06.
- ↑ "Cefcapene Pivoxil Hydrochloride Hydrate: Korea Drug Master Files (KDMF)". PharmaCompass. Retrieved 2026-08-06.
- ↑ Kim, Jisun (2024-09-11). "Yungjin Pharm Signs Antibiotic Export Contract Worth KRW 100 Billion with Chinese Pharmaceutical Company". Alpha Biz. Retrieved 2026-08-06.
- ↑ "Proper Use of Drugs Alert No. 17: Hypoglycemia Associated with Oral Pivoxil-Group Antibacterials in Children" (PDF). Pharmaceuticals and Medical Devices Agency. June 2026. Retrieved 2026-08-06.
